| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.07 | 38.1% | 61.4% |
| Total Income | 1.07 | 38.1% | 61.4% |
| Expenditure | 9.99 | 7.2% | 55.7% |
| PBT | — | ||
| Net Profit | 1.48 | 130.8% | 104.9% |
| OPM | — | ||
| NPM | 100.00% | ||
| EPS | 0.01 | 150.0% | 107.7% |
Lineage Cell Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
07 Aug 2026 · 7 Aug, 1:53 am
Summary
Lineage Cell Therapeutics reported its second quarter 2026 financial and operating results, with total revenues of $1.1 million, a decrease from the prior year, primarily due to lower collaboration revenue. Operating expenses decreased significantly to $10.0 million, largely driven by a prior year impairment charge. The company achieved a net income of $1.5 million for the quarter, a substantial improvement from the net loss in Q2 2025. Management highlighted progress in its clinical pipeline, including positive data for OpRegen and advancements in its COR1 program, while noting that cash reserves are expected to support operations into Q3 2028.
Key Highlights
- 1
Lineage Cell Therapeutics reported total revenues of $1.1 million for the three months ended June 30, 2026, a decrease of $1.7 million compared to the same period in 2025.
- 2
Total operating expenses for the three months ended June 30, 2026, were $10.0 million, a decrease of $12.5 million compared to the same period in 2025.
- 3
The company reported a net income of $1.5 million, or $0.01 earnings per share (basic), for the three months ended June 30, 2026, compared to a net loss of ($30.5) million in the prior year period.
- 4
Cash, cash equivalents, and marketable securities as of June 30, 2026, were $50.8 million, expected to support planned operations into Q3 2028.
- 5
Positive 3-year Phase 1/2a clinical data of RG6501 (OpRegen®) was featured at the Retinal Therapeutics Innovation Summit 2026.
- 6
The company announced progress with its wholly-owned corneal endothelial disease cell therapy program (COR1).
- 7
A Scientific Advisory Board was established with cell therapy executive Joachim Fruebis, PhD, as a founding member.
Management Comments
Brian M. Culley
As we continue to support our collaboration with Roche and Genentech for their clinical development of OpRegen, Lineage remains focused on building out our allogeneic cell transplant pipeline. Our most recent advancement is COR1, our wholly-owned corneal endothelial cell (CEnC) therapy preclinical program, which we believe highlights the value of our pluripotent cell-based therapeutic platform to be able to generate novel assets with differentiated and potentially superior characteristics. COR1 benefits from our existing ophthalmology and manufacturing expertise and represents a natural next application of our platform. Notably, only nine months after internal lab work began, we successfully utilized our proprietary AlloSCOPETM 5D technology to achieve seamless bioreactor-based precursor expansion and differentiation to support large-scale CEnC production. We believe this expansion and differentiation capability, together with a thaw-and-inject formulation, can support the development of an exciting and potentially disruptive asset in corneal disease. The COR1 program, together with others in our pipeline, reflects Lineage’s balanced business strategy: to provide manufacturing support for Roche and Genentech’s clinical development of RG6501 while also prioritizing programs that we believe can potentially generate meaningful data from early clinical trials, which could allow us to evaluate clinical potential earlier, optimize capital allocation, and accelerate value creation.
Informational and educational content only. Not investment advice.